# PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer

> **NCT04404361** · PHASE2 · TERMINATED · sponsor: **CTI BioPharma** · enrollment: 200 (actual)

## Conditions studied

- COVID19
- COVID-19
- COVID

## Interventions

- **DRUG:** Pacritinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04404361
- **Lead sponsor:** CTI BioPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-05-22
- **Primary completion:** 2021-09-21
- **Final completion:** 2021-09-21
- **Target enrollment:** 200 (ACTUAL)
- **Why stopped:** decision to close enrollment early
- **Last updated:** 2024-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04404361

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04404361, "PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04404361. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*